01—Abstract
Summary
Summary of the 8-K filed July 29, 2026. Cited figures are marked; the original filing is the authoritative source.
Biogen reported second quarter 2026 total revenue of $2.74 billiona, up 3% year-over-year (2% at constant currency).
Growth Portfolio revenue reached $1.06 billionb, up 24%, and exceeded Legacy MS revenue of $767 million for the first time, which management presents as evidence of the company's repositioning. Product-level results were mixed: SKYCLARYS (+29%), ZURZUVAE (+53%), EMPAVELI (+123%) and LEQEMBI global in-market sales (+15%) grew strongly, while MS product revenue fell 13% and VUMERITY declined 7% on inventory dynamics. SYFOVRE and EMPAVELI contributed revenue after the Apellis acquisition closed on May 14, 2026.
Profitability fell sharply. GAAP diluted EPS was $0.66c versus $4.33 a year ago, and Non-GAAP diluted EPS was $3.60 versus $5.47, reflecting $164 million of acquired IPR&D and milestone expense, higher SG&A from Apellis and launch spending, and higher interest expense tied to the transaction financing. Free cash flow was $408 million, and net debt stood at about $6.8 billion at June 30, 2026, after total debt rose to roughly $8.1 billion.
Full-year 2026 guidance is internally split. Underlying Non-GAAP EPS guidance was raised $0.60 to $15.85d to $16.85, but reported Non-GAAP guidance was cut to $12.00 to $13.00 from $15.25 to $16.25.
The reduction reflects roughly $3.00 of acquired IPR&D and milestone charges and about $0.85 of Apellis dilution. Management expects the deal to be accretive in 2027, with run-rate synergies of at least $250 million exiting 2027, and it guides to five registrational readouts over the next four quarters.
02—Key points
Key Highlights
- Q2 2026 total revenue of $2.74 billion rose 3% year-over-year; Growth Portfolio revenue of $1.06 billion grew 24% and exceeded Legacy MS revenue of $767 million.
- Non-GAAP diluted EPS fell to $3.60 from $5.47 (down 34%), and GAAP diluted EPS fell to $0.66 from $4.33, driven by $164 million of acquired IPR&D and milestone expense, Apellis-related costs and higher interest expense.
- Full-year 2026 reported Non-GAAP EPS guidance was lowered to $12.00 to $13.00 from $15.25 to $16.25, although underlying guidance was raised $0.60 to $15.85 to $16.85; the gap reflects about $3.00 of IPR&D/milestone charges and about $0.85 of Apellis dilution.
- Apellis acquisition closed May 14, 2026; SYFOVRE Q2 revenue was $162 million (up 8%, strongest quarter since launch) and EMPAVELI was $46 million (up 123%), with Biogen recognizing $97 million and $30 million respectively post-close.
- Management expects at least $250 million of run-rate synergies exiting 2027 and reiterates that the Apellis deal remains on track to be accretive to Non-GAAP EPS in 2027.
- Pipeline catalysts: litifilimab SLE registrational data expected by end of 2026; litifilimab CLE, felzartamab AMR and zorevunersen Dravet Phase 3 readouts expected in 2027; Biogen plans to advance diranersen (tau-directed, Alzheimer's) to Phase 3 after Phase 2 proof-of-concept.
- Balance sheet: cash of about $1.3 billion, total debt of about $8.1 billion (net debt about $6.8 billion), and Q2 free cash flow of $408 million, compared with $1.0 billion of cash and marketable securities falling from $4.2 billion at year-end 2025.
03—Questions
Frequently Asked Questions
Why did reported 2026 EPS guidance drop even though underlying guidance was raised?
Underlying Non-GAAP EPS guidance increased by $0.60 to $15.85 to $16.85. However, reported guidance now reflects roughly $3.00 per share of acquired IPR&D and milestone charges (up about $2.00 from April) and about $0.85 per share of expected dilution from the Apellis acquisition, leading to a reported range of $12.00 to $13.00. Biogen does not guide to GAAP items beyond revenue, so these charges are estimates tied to transactions and milestones.
Is the Growth Portfolio strategy working?
Growth Portfolio revenue rose 24% year-over-year to $1.06 billion and surpassed Legacy MS revenue of $767 million in Q2. Key drivers were SKYCLARYS (+29%), ZURZUVAE (+53%), SPINRAZA (+2%, with high-dose conversion ahead of expectations), and the two Apellis products. Weaknesses include VUMERITY (down 7% in Q2, though up 7% in the first half) and the decline in MS product revenue of 13%.
What is the financial impact of the Apellis acquisition?
Apellis closed May 14, 2026, and Biogen expects about $0.85 of dilution to 2026 Non-GAAP EPS, mainly from lower interest income and higher interest expense on transaction financing. Total debt rose to about $8.1 billion, and the notes payable figures show a current portion of $800 million. Management expects the deal to be accretive in 2027 and to deliver at least $250 million of run-rate synergies exiting 2027.
What major clinical readouts should investors watch?
Management expects five registrational readouts over the next four quarters: litifilimab in SLE by end of 2026, and litifilimab in CLE, felzartamab in AMR, and zorevunersen in Dravet syndrome next year. Diranersen showed Alzheimer's proof-of-concept as the first tau-directed agent to show clinical efficacy and reduce brain tau pathology, and Biogen plans to advance it to Phase 3. BIIB091 achieved Phase 2 proof-of-concept in relapsing-remitting MS, with next steps still under evaluation.
Why did GAAP results decline so much in Q2?
GAAP diluted EPS fell to $0.66 from $4.33. Contributing factors included $164 million of acquired IPR&D, upfront and milestone expense (including a $15 million Ionis license fee for BIIB147); $165 million of restructuring charges; higher amortization and impairment of acquired intangibles ($168 million, versus $131 million a year ago); $38 million of step-up amortization in R&D related to SKYCLARYS inventory used in trials; and a GAAP effective tax rate of 26.4%, partly due to non-deductible Apellis-related expenses.
04—Continue